Introduction
Invasive candidiasis (IC) is the leading cause of fungal disease among hospitalized patients, and is associated with considerable morbidity and mortality and a high cost burden. 1 Early treatment in patients with proven candidaemia is associated with reduced mortality 1 and consequently this has produced an increase in early antifungal treatment in patients with risk factors for IC. [2] [3] [4] [5] However, IC is frequently not confirmed until after 3-5 days of empirical treatment, and in this case whether to stop or to continue antifungal agents is a real clinical challenge with influence in antifungal stewardship programmes. 6 V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
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In the last decade, strategies including biomarkers [b-D-glucan (BDG) or Candida albicans germ tube antibodies (CAGTA)], surveillance cultures or predictive scores have been investigated not only for starting [7] [8] [9] but also for discontinuing empirical antifungals. 10, 11 Our own data, and those of Nucci et al.
11
, suggest that patients with negative BDG and CAGTA results and with unconfirmed IC after 5-7 days of treatment may be candidates for early discontinuation of antifungal agents. 10, 11 T2Candida magnetic resonance (T2MR) is a new diagnostic method for candidaemia, with an overall specificity of 99.4% and sensitivity of 91.1%. 12 To the best of our knowledge, its role in the management of patients receiving empirical antifungal agents due to suspected IC has not been evaluated. Therefore, we conducted a study to assess the potential role of T2MR alone and combined with serological biomarkers (BDG or CAGTA) and standard cultures for the early prediction of a good/poor patient outcome in order to identify patients who would most benefit from discontinuation or maintenance of empirical antifungal therapy.
Patients and methods

Study population and setting
This was a prospective observational pilot study conducted in four hospitals located in Madrid, Spain. From January to June 2017, adult (.18 years) hospitalized patients who received systemic antifungal therapies for suspected IC were screened daily. The initiation of empirical antifungal treatment was based on the criteria specified in the IDSA guidelines. 13 Pregnant women, haematological patients and those who had received .72 h of empirical antifungal therapy were not included. Patients were followed throughout the study period and for at least 1 month after they completed antifungal treatment.
Tests performed
Blood samples were collected by venepuncture to perform BDG, CAGTA and T2MR at the time the patient signed the informed consent (baseline, day 0) and then on day !2 and day !4. Only BDG and CAGTA results were reported to the attending clinicians; T2MR results were provided only at the end of the study and thus had no influence on the clinical management of the patients. Other routine microbiological (blood culture, catheter culture and culture of other clinical samples) and radiological tests were also performed according to conventional clinical practice and local guidelines.
Definition of IC episode and Candida colonization
IC included candidaemia and deep-seated candidiasis, 14 which were respectively defined as: (i) the presence of Candida in blood in a patient with consistent clinical manifestations; and (ii) isolation of Candida species from normal sterile body fluids or peritoneal fluid obtained during surgery or by percutaneous aspiration or by drainage inserted for ,24 h. Colonization was defined as the recovery of Candida species from non-sterile sites (urine, stool, drainage .24 h), independently of the presence of signs or symptoms attributable to the clinical suspicion of IC.
Definition of poor outcome episode
Poor outcome was defined as either diagnosis of IC and/or death within the first 7 days after starting empirical antifungal therapy, without another definitive identifiable cause. We decided to choose this definition because, from a clinical point of view, patients at risk of a poor outcome are purportedly those who could most benefit from empirical antifungal treatment. 
Data collection
Laboratory procedures
BDG, CAGTA and T2MR samples were frozen at #20 C until processed. All tests were performed twice weekly at the clinical laboratory of the coordinating centre (Hospital General Universitario Gregorio Marañón).
Serological detection of BDG was performed using the Fungitell assay kit (Associates of Cape Cod) according to the manufacturer's instructions. Results were read and analysed with a BioTek ELX808TM Microplate Reader and GEN5 Software (BioTek U.S., VT, USA) and considered positive when the values were 80 pg/mL. 10 For the CAGTA assay, serum samples were processed according to the manufacturer's recommendations (Vircell Microbiologist S.L., Granada, Spain). Samples were considered positive above a cut-off of 1/160.
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T2MR (T2 Biosystems Inc.) was performed in EDTA whole-blood samples obtained from a peripheral vein and processed automatically following all the steps previously described by Mylonakis et al. 12 The technique detected the five most frequent species involved in IC, grouped according to their resistance patterns:
13 C. albicans/C. tropicalis, C. krusei/C. glabrata and C. parapsilosis. If the internal control was invalid and there were no positive T2MR signals, an 'invalid' result was displayed, indicating that the specimen may have contained inhibitors that could have interfered with Candida detection. 12 
Data analysis
All analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). For all calculations, a P value ,0.05 was considered significant. Qualitative variables appear with their frequency distribution. Quantitative variables are expressed as the median and IQR. Groups were compared using the Fisher exact test for categorical variables and the Mann-Whitney test for continuous variables. A multivariate logistic regression model was used to assess predictors of poor outcome.
Performance characteristics [sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)] of the prediction rule for poor outcome were composed of standard cultures, biomarkers and T2MR at different timepoints. The goals of combining diagnostic procedures were to maximize the PPV (identifying patients at high likelihood of poor outcome in whom antifungal therapy should be maintained) while maintaining a high sensitivity (identifying a significant number of patients with poor outcome as positive).
Ethics
This study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañon (number 2016-024) and the Spanish Agency for Medicines and Health Care Products. Written consent was deemed necessary.
Results
Fifty-four consecutive patients who received empirical antifungal therapy for presumed IC were invited to participate in the study. Of T2MR for patients with suspected invasive candidiasis JAC these, five were not included in the final analysis for the following reasons: three (5.6%) invalid T2MR results, one (1.9%) proven infection caused by a Candida species not included in T2MR (secondary peritonitis due to C. kefyr) and one patient who did not sign the informed consent. The remaining 49 patients constitute the basis of our report. Table 1 summarizes the demographics and clinical characteristics of the 49 patients included. Most patients were male (65.3%) and the mean age was 64.7 years. Overall, 38 patients were admitted to ICU (77.6%) and 11 to other wards (14.3% medical and 8.2% surgical). The main indications for starting empirical antifungal therapy were severe sepsis or septic shock (69.4%) and having a central venous catheter in place (71.4%) or high-risk gastrointestinal surgery (63.3%). Echinocandins accounted for 85.7% of the empirical therapy and the mean (+SD) duration of antifungal therapy was 9.5 days (+6.8 days).
Description of the groups
According to our definition, 35 patients (71.4%) had a good outcome and 14 (28.6%) had a poor outcome. Among poor-outcome patients, seven (50.0%) died within 7 days of starting empirical antifungal therapy and the other seven (50.0%) had a diagnosis of deep-seated candidiasis, one with candidaemia. Overall, intraabdominal infections accounted for 85.7% (6/7) of the deepseated candidiasis cases.
Details from these patients are provided in Table S1 (available as Supplementary data at JAC Online). The C. parapsilosis that caused the fungaemia of intra-abdominal origin was detected by the T2MR instrument 8 days before blood cultures became positive.
No differences were observed between the poor-and goodoutcome groups with regard to age, sex, hospital ward, underlying disease, reason for empirical antifungal therapy, type of antifungal therapy, previous Candida colonization and positive CAGTA or positive BDG assay (Table 1 ). However, compared with patients with good outcome, those with poor outcome had more rapidly fatal underlying disease according to McCabe scale (0% versus 28.6%, P 0.001) and received longer antifungal therapy, although the difference was not statistically significant (mean days 8.4 versus 12.3, P " 0.06).
As for biomarkers, CAGTA and BDG could not differentiate these populations, since the results were positive in a significant number of patients with good outcome [baseline positive CAGTA, 8/35 (22.9%); positive BDG, 17/35 patients (48.6%)]. In contrast, baseline T2MR was significantly more common in patients with poor outcome versus patients with good outcome [5/14 (35.7%) versus 0/35 (0.0%), P " 0.001]. Interestingly, among patients with good clinical outcome, baseline T2MR was always negative. The T2MR result became positive on day !2 in two patients (5.7%); both had septic shock and multiple Candida colonization, but had no definitive diagnosis of IC, and had a good outcome.
After adjusting for age, sex, severity of underlying disease and clinical presentation, the multivariate analysis (data not shown) identified a positive T2MR performed at baseline as an independent predictor of poor outcome (OR 26.4, 95% CI 2.1-327.3, P " 0.01).
Performance of T2MR, CAGTA, BDG and cultures, alone or in combination, for identification of patients with poor outcome Table 2 summarizes the sensitivity, specificity and predictive values of the three techniques (BDG, CAGTA and T2MR) for identification of patients with poor outcome at different timepoints (baseline, day !2 and day !4). For all three procedures, the results were better when tests were performed at baseline. The best efficacy was achieved with T2MR, with a sensitivity of 35.7% (95% CI 13.9%-64.3%), a specificity of 100% (95% CI 87.6%-100%), a PPV of 100% (95% CI 46.3%-100%) and an NPV of 79.6% (95% CI 64.2%-89.6%).
When we analysed the efficacy of the combination of different biomarkers with standard cultures (Table 3) , the best results were obtained with baseline T2MR combined with standard cultures. Figure 1 depicts the receiver operating characteristic (ROC) curves for these combinations at baseline. The combination of baseline T2MR with standard cultures showed the highest AUC (0.85), in comparison with that of CAGTA/standard culture (0.67) and BDG/standard culture (0.65) combinations.
Discussion
In this prospective cohort of hospitalized patients at high risk of IC, we found that a positive early T2MR was independently associated with a poor outcome, defined as ultimate demonstration of IC or unexplained death. In fact, baseline T2MR was always negative in patients with good outcome, so it may purportedly be a marker for early discontinuation of empirical antifungals.
Clinical suspicion of IC is common in critically ill patients, and, given the limitations of blood cultures for the diagnosis of deepseated candidiasis, [17] [18] [19] [20] [21] patients with suspected IC often receive empirical antifungal therapy for 10-14 days. 6 Other studies have demonstrated that the incidence of IC in these populations is relatively low, 22, 23 very similar to the 14% found in our study. Therefore, many patients may receive unnecessary antifungals with a negative impact on resistance rates, 24 adverse effects and healthcare costs. 3, 25 Although the utility of empirical antifungal therapy in high-risk ICU patients has been recently questioned, 23 the fact is that it remains a common practice both inside and outside ICUs. Accordingly, there is a clear need to differentiate patients who could really benefit from antifungal therapy from patients in whom therapy could be stopped early. [26] [27] [28] Standard biomarkers and cultures require at least 5-7 days and the experience with early withdrawal of therapy is very limited. 10, 11 T2MR is a new, fully automated, nano-diagnostic test that can detect molecular targets of Candida species within whole-blood specimens, without the need for prior isolation, 29 providing results within 4 h. These early results could prove essential for stopping unnecessary treatments, and thus we evaluated its potential role as a marker for good prognosis in patients in whom empirical antifungal therapy had been started.
Notably, in the present study, we found that a positive T2MR in a sample obtained within the first 72 h of empirical therapy (baseline) had a specificity of 100% for identifying poor-outcome patients. Moreover, our study demonstrates that when combined with standard cultures, the sensitivity reached 71.4%, while the PPV remained 100%. Considering these results, a possible recommendation would be to consider stopping empirical antifungal therapy in patients with negative baseline T2MR and with negative cultures, and to maintain a full course in those with a positive test. With this approach, antifungal therapy could have been drastically shortened in 33/49 (67.3%) high-risk patients included in the present study.
There are potential limitations of our study. First, in our study all patients had received a mean of 2 days of antifungal therapy before samples were obtained, and results of the T2MR were not transmitted to the clinician. Accordingly, a prospective comparative study should be done to evaluate the safety of our proposed approach to empirical antifungal therapy. Until such a study is available, experts in the field should make decisions. Second, since we excluded from the analysis one patient with C. kefyr peritonitis (not detectable by T2MR), the diagnostic value of the T2MR may have been overestimated. Third, because the T2MR panel includes only five species of Candida, we did not consider in our analysis the possibility of T2MR-negative patients that are infected by other Candida species. Consequently, despite the fact that T2MR-positive patients are candidates for a poor outcome, patients with a negative baseline T2MR need a negative culture confirmation in order to consider stopping empirical antifungal therapy early. Fourth, no patient was subjected to autopsy examination. Consequently, we cannot confirm that patients who died in the first 7 days actually had an IC. On the other hand, the strengths of our proof-ofconcept study include its prospective nature and the fact that it was derived from a cohort of patients in four large academic medical centres and thus the results may be generalizable to other settings.
In conclusion, in our cohort of patients with a presumed diagnosis of IC, T2MR, in combination with standard cultures, demonstrated a high discriminative ability for identifying patients with a high risk of dying or developing IC. Taken in the context of other clinical and microbiological tests, this new diagnostic tool may be of significant utility in the identification of patients who may really benefit from antifungal therapy. Future studies designed to evaluate the impact of our findings on diagnosis, treatment, outcomes and healthcare costs are warranted. 
